Amneal Pharmaceuticals vs Perrigo
AMRX and PRGO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMRX and PRGO compare
Amneal Pharmaceuticals is the larger company, worth 3.0 times as much as Perrigo ($6.8B against $2.3B).
Amneal Pharmaceuticals grew revenue faster over the last twelve months (8.9% versus −4.5% for Perrigo).
Amneal Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 4.2% compared with −43.3% at Perrigo.
Perrigo pays a dividend yielding 5.4%; Amneal Pharmaceuticals does not pay one.
Amneal Pharmaceuticals scores higher on the StockData Score (12 against 10 for Perrigo), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMRX | PRGO |
|---|---|---|
| Size and price | ||
| Market cap | $6.8B | $2.3B |
| Share price | $21.38 | $16.24 |
| Change, 1 year | 79.7% | 14.7% |
| Change, 5 years | 363% | −60.5% |
| Beta (5Y) | 1.07 | 0.59 |
| Employees | 8,500 | 8,100 |
| StockData Score | ||
| Total score | 12 (better) | 10 |
| Valuation score | 0 | 3 (better) |
| Growth score | 5 (better) | 0 |
| Performance score | 5 (better) | 2 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | 50.9× | – |
| P/S | 2.1× | 0.6× (better) |
| P/B | 12.9× | 0.9× (better) |
| EV/EBITDA | 20.1× | – |
| P/FCF | 77.4× | 13.4× (better) |
| FCF yield | 1.3% | 7.5% (better) |
| Fair value | $13.10 | $22.75 |
| Margin of safety | −63.2% | 28.6% (better) |
| Growth | ||
| Revenue growth (TTM) | 8.9% (better) | −4.5% |
| Revenue growth, 5Y average | 8.7% (better) | 0.79% |
| Net income growth (TTM) | 2159% | – |
| EPS growth (TTM) | 2000% | – |
| EPS growth, 5Y average | −18.5% | – |
| Profitability | ||
| Gross margin | 40.2% (better) | 32.3% |
| Operating margin | 15.0% (better) | −39.4% |
| Net margin | 4.2% (better) | −43.3% |
| FCF margin | 2.8% | 4.1% (better) |
| Return on equity | 63.2% (better) | −51.4% |
| Return on invested capital | 16.3% (better) | −19.7% |
| Financial health | ||
| Debt / equity | 5.53 | 1.35 (better) |
| Net debt / EBITDA | 5.81 | – |
| Current ratio | 1.87 | 2.35 (better) |
| Altman Z-score | 1.88 (better) | −0.43 |
| Piotroski F-score | 7 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | – | 5.4% |
| Years of dividend growth | – | 11 |
| Dividend growth, 5Y average | – | 5.2% |
| Shareholder yield | 0.00% | 5.4% (better) |
| Ownership | ||
| Held by institutions | 52.7% | 116% |
| Held by insiders | 60.7% | 0.36% |
| Insider net buying, 12 months | −$7.7M | $0 (better) |
| Short interest, % of float | 9.1% | 17.8% |
Go deeper
- AMRX stock overview
- AMRX income statement
- AMRX valuation and score
- PRGO stock overview
- PRGO income statement
- PRGO valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.